Global Gene Therapy Market Trends to 2025
November 10, 2015 21:56 ET
|
Research and Markets
Dublin, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/w5chcx/gene_therapy) has announced the addition of the "Gene Therapy Market,...
BioCancell Advances Intellectual Property Portfolio in the United States
November 06, 2015 08:00 ET
|
BioCancell
JERUSALEM, ISRAEL--(Marketwired - Nov 6, 2015) - BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
BioCancell Advances Phase III Clinical Program for Bladder Cancer
October 01, 2015 08:00 ET
|
BioCancell Ltd.
JERUSALEM, ISRAEL--(Marketwired - Oct 1, 2015) - BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
BioCancell Receives FDA Fast Track Designation for BC-819 for Treatment of Bladder cancer Patients
September 10, 2015 08:00 ET
|
BioCancell Ltd.
JERUSALEM, ISRAEL--(Marketwired - Sep 10, 2015) - BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
Foamix Announces Appointment of Dr. Aaron Schwartz to Board of Directors
May 07, 2015 08:30 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., May 7, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing...